BY THE NUMBERS
| Category | Key Statistics |
|---|---|
| Total number of rare diseases | 10,000+ |
| Americans affected by rare diseases | 25–30 million (1 in 10 people) |
| Percent of rare diseases that are genetic | ~80% |
| Rare diseases that cause peripheral neuropathy | ~100–150 |
| Types of rare diseases that cause neuropathy | Genetic, autoimmune, metabolic, mitochondrial, paraneoplastic, infectious, toxic exposure |
Rare research. Universal impact.
Peripheral neuropathy is a generic syndrome that may be caused by a few common diseases (e.g., diabetes) and/or by many different types of rare diseases (e.g., pathogenic gene variants).
Rare diseases act as precision windows into human biology: when a single gene or pathway is disrupted in a small patient population, it reveals mechanisms that are shared across many common conditions. Breakthroughs in rare disorders routinely ripple outward. The recent FDA-approved therapy for SORD deficiency, for example, emerged from studying a tiny group of patients with a rare neuropathy—yet the same metabolic pathway is now being explored as a treatment target for forms of diabetes that affect millions. Likewise, research into high-specificity sodium-ion-channel inhibitors—initially developed for ultra-rare channelopathies—has created a platform for designing next-generation modulators of other ion channels. These tools may ultimately transform care for autonomic neuropathy, small-fiber neuropathy, cardiac conduction disorders, gastrointestinal dysmotility, and other conditions rooted in electrical signaling. Rare-disease science doesn’t just solve the rare; it builds the mechanistic blueprints that advance medicine for everyone.
